Acyclovir

Regulatory News:

BioAlliance Pharma SA (Paris:BIO) today announced that it has
entered into an exclusive licensing agreement under which Korea-based
Handok Pharmaceuticals will receive commercialization rights in Korea,
Taiwan, Singapore and Malaysia. BioAlliance Pharma’s innovative,
muco-adhesive antifungal therapy Loramyc(TM) (miconazole Lauriad(R))
is already approved in Europe and a Phase III clinical trial has just
completed in the United States.

BioAlliance Pharma’s third commercial partnership is potentially
worth $12 million to the Paris-based firm, including $1.5 million on
signature and a further $1.5 million on first sale in Korea - the
remainder being sales milestones (up to $9 million) in the designated
territory and double-digit royalties commensurate with the product
stage.

“Handok is the ideal partner, with good marketing capabilities for
South East Asia. We are delighted to be able to introduce Loramyc to
the Asian market through this company”, said Dominique Costantini
(BioAlliance Pharma’s President and CEO) after the signing ceremony in
Seoul. She added that “Handok has a longstanding relationship with
major pharmaceutical companies and a track record in successfully
commercializing the latter’s products in this geographic zone. We
shall continue our efforts to make Loramyc(TM) available worldwide in
due course through strategic partners like Handok”.

Mr. Young-jin Kim (CEO of Handok Pharmaceuticals) commented: “We
are very pleased to be teaming up with BioAlliance Pharma on this
innovative product, which has good efficacy and will help to improve
the patients’ quality of life. Handok plans to launch Loramyc(TM) in
2010. We expect to establish a mutually beneficial, long-term
partnership with BioAlliance Pharma because this agreement opens the
door to more products from both BioAlliance and the world of biotech
and will contribute to Handok’s continued expansion”.

About BioAlliance Pharma

BioAlliance Pharma SA is a specialty pharmaceutical company
focused on the treatment of opportunistic infections in cancer and
HIV. The company develops and commercializes innovative products which
address resistance issues. The company has launched its first
portfolio product (Loramyc(R)) in France and the compound is currently
in Phase III clinical development in oropharyngeal candidiasis in the
USA. In addition, two other innovative products are currently in Phase
III clinical trials: acyclovir Lauriad(R) in oral herpes (based on the
same Lauriad(R) muco-adhesive technology as Loramyc(R), which enables
targeted release at the disease site) and doxorubicin Transdrug(R) in
primary liver cancer (based on the Transdrug(R) nanoparticle
technology, designed specifically for intracellular targeting of
resistant cells). The company is also developing a new therapeutic
entities program focused on the oncology and infectious disease
markets.

In 2007, the company has established strategic alliances for
commercializing Loramyc(R) in Europe (with JV SpeBio) and the USA
(with Par Pharmaceutical). For more information, visit BioAlliance
Pharma’s website at http://www.bioalliancepharma.com.

About Handok Pharmaceuticals

Handok Pharmaceuticals is a Korean-based pharma company founded in
the 1950s via an alliance with Hoechst and then extended through a JV
in the 1960s. In the 1970s, the company also formed a strategic
alliance with Roussel Uclaf and, on the diagnostic side, with Behring.
In 2000, Handok formed a new strategic partnership with
Sanofi-Aventis. 2007 sales amounted to $250 million and the company
also has major GMP manufacturing capabilities. Handok is well
established in Korea and has established a new alliance with YSP in
Taiwan. Its main product lines are in the digestive field,
cardiovascular diseases and diabetes treatments. In the hospital
prescription sector, Handok develops post-chemotherapy anti-emetic
treatments, anti-infectives and haematological treatments.

For more information, visit the Handok website at
http://www.handok.co.kr

Disclaimer

This communication expressly or implicitly contains certain
forward-looking statements concerning BioAlliance Pharma SA and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors, which could cause the actual results,
financial condition, performance or achievements of BioAlliance Pharma
SA to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
BioAlliance Pharma SA is providing this communication as of this date
and does not undertake to update any forward-looking statements
contained herein as a result of new information, future events or
otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements
of BioAlliance Pharma SA to differ from those contained in the
forward-looking statements, please refer to the Risk Factors
(”Facteurs de Risque”) section of the reference document approved by
the AMF on April 6 2007 under the number R. 07-031, which is available
on the AMF website (http://www.amf-france.org) or on BioAlliance
Pharma S.A.’s website (http://www.bioalliancepharma.com).

source